Search
Talimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalTalimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. … It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities.
Categories: Complex MixturesQuinethazone
go.drugbank.com/drugs/DB01325ApprovedQuinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Rifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawnThe parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. … [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801]
Pegzilarginase
go.drugbank.com/drugs/DB14780ApprovedPegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D). … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. … [A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709]
Iobitridol
go.drugbank.com/drugs/DB12407ApprovedWithdrawnIobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.
Categories: Compounds used in a research, industrial, or household settingValoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States. … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.
Categories: Complex MixturesSGS-742
go.drugbank.com/drugs/DB05010InvestigationalSGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.
Categories: Compounds used in a research, industrial, or household settingSynonyms: (3-Aminopropyl)(n-butyl)phosphinic acidTucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. … It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.
Melphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnIt has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … Melphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan].